These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26445961)

  • 1. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.
    Mantopoulos T; Mitchell PM; Welton NJ; McManus R; Andronis L
    Eur J Health Econ; 2016 Nov; 17(8):927-938. PubMed ID: 26445961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data.
    Willan AR; Briggs AH; Hoch JS
    Health Econ; 2004 May; 13(5):461-75. PubMed ID: 15127426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods for covariate adjustment in cost-effectiveness analysis that use cluster randomised trials.
    Gomes M; Grieve R; Nixon R; Ng ES; Carpenter J; Thompson SG
    Health Econ; 2012 Sep; 21(9):1101-18. PubMed ID: 22461149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations.
    Nixon RM; Thompson SG
    Health Econ; 2005 Dec; 14(12):1217-29. PubMed ID: 15945043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial factorial trials: comparing methods for statistical analysis and economic evaluation.
    Dakin HA; Gray AM; MacLennan GS; Morris RW; Murray DW
    Trials; 2018 Aug; 19(1):442. PubMed ID: 30115104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A framework for cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW
    Health Econ; 2001 Jun; 10(4):303-15. PubMed ID: 11400253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian models for cost-effectiveness analysis in the presence of structural zero costs.
    Baio G
    Stat Med; 2014 May; 33(11):1900-13. PubMed ID: 24343868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.
    Manca A; Rice N; Sculpher MJ; Briggs AH
    Health Econ; 2005 May; 14(5):471-85. PubMed ID: 15386662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials.
    Gomes M; Ng ES; Grieve R; Nixon R; Carpenter J; Thompson SG
    Med Decis Making; 2012; 32(2):350-61. PubMed ID: 22016450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?
    O'Hagan A; Stevens JW
    Health Econ; 2003 Jan; 12(1):33-49. PubMed ID: 12483759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility.
    Manca A; Hawkins N; Sculpher MJ
    Health Econ; 2005 May; 14(5):487-96. PubMed ID: 15497198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice.
    Ng ES; Diaz-Ordaz K; Grieve R; Nixon RM; Thompson SG; Carpenter JR
    Stat Methods Med Res; 2016 Oct; 25(5):2036-2052. PubMed ID: 24346164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.